Feasibility of Telemedicine Medical Abortion

TelAbortion: Medical Abortion by Direct-to-patient Telemedicine and Mail

This pilot study is designed to obtain data on the safety, acceptability, and feasibility of providing abortion by direct-to-patient telemedicine and mail.

Study Overview

• Status: Completed
• Conditions: Pregnancy
• Intervention / Treatment: Drug: medical abortion

• Study Type: Observational
• Enrollment (Actual): 413

Contacts and Locations

Study Locations

• United States
  • Colorado
    • Denver, Colorado, United States, 80207
      • Planned Parenthood of the Rocky Mountains
  • District of Columbia
    • Washington, District of Columbia, United States, 20815
      • Carafem
  • Georgia
    • Atlanta, Georgia, United States, 30309
      • Carafem
  • Hawaii
    • Honolulu, Hawaii, United States, 96826
      • The University of Hawaii Women's Options Centers
  • Illinois
    • Skokie, Illinois, United States, 60076
      • Carafem
  • Iowa
    • Iowa City, Iowa, United States, 52245
      • Emma Goldman Clinic
  • Maine
    • Augusta, Maine, United States, 04332
      • Maine Family Planning
  • Maryland
    • Chevy Chase, Maryland, United States, 20815
      • Carafem
  • Massachusetts
    • Boston, Massachusetts, United States, 02134
      • Maine Family Planning
  • Minnesota
    • Saint Paul, Minnesota, United States, 55114
      • Planned Parenthood Minnesota, North Dakota, South Dakota
  • Montana
    • Billings, Montana, United States, 59102
      • Planned Parenthood of Montana
  • New Mexico
    • Albuquerque, New Mexico, United States, 80207
      • Planned Parenthood of the Rocky Mountains
  • New York
    • New York, New York, United States, 04332
      • Maine Family Planning
  • Oregon
    • Portland, Oregon, United States, 97212
      • Planned Parenthood Columbia Willamette
  • Washington
    • Vancouver, Washington, United States, 97212
      • Planned Parenthood Columbia Willamette

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years to 50 years (Child, Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

People seeking abortion

Description

Inclusion Criteria:

• desires abortion

Exclusion Criteria:

• medically ineligible for procedure

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Pregnant people	Drug: medical abortion; medical abortion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of participants with adverse events	2 years

Collaborators and Investigators

• Sponsor: Gynuity Health Projects

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2020
• Primary Completion (Actual): October 1, 2021
• Study Completion (Actual): October 1, 2021

Study Registration Dates

• First Submitted: October 19, 2020
• First Submitted That Met QC Criteria: October 22, 2020
• First Posted (Actual): October 23, 2020

Study Record Updates

• Last Update Posted (Actual): February 4, 2022
• Last Update Submitted That Met QC Criteria: February 3, 2022
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: 1049

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes